Albendazole - GSK
Alternative Names: Albenza; Bilutac®; Escazole®; Eskazole®; Proftril®; SKF 62979; Zentel®Latest Information Update: 02 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK; PharmAust
- Class Anthelmintics; Benzimidazoles; Carbamates; Small molecules
- Mechanism of Action Tubulin inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Helminthiasis
- Discontinued Ascites
Most Recent Events
- 03 Feb 2021 Discontinued - Phase-I for Helminthiasis (In volunteers) in China (PO) (GlaxoSmithKline pipeline, February 2021)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Helminthiasis(In volunteers) in China (PO, Tablet)
- 31 May 2013 Phase-I/II clinical trials in Ascites in Australia (PO)